Obermatt
See Similar Stocks →

Mirum Pharmaceuticals

NMQ:MIRM · US6047491013
BiotechnologyMedium

360

40
Profit price38
Owner Earnings Yield1
Dividend Yield1
Price/Sales26
EV / Gross Profit48
Price/Book1
Return on Capital60
Cash Return on Capital4
Return on Equity1
EBIT Margin31
Gross Profitability86
Accruals100
Owner Earnings Margin34
Sales growth75
Profit growth4
Reinvestment70
Price momentum84
Debt load29
Refinancing36
Debt Payback1
Liquidity29
Analyst ratings66
Opinion Changes92
Price Target Upside51
Market mood77
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Mirum Pharmaceuticals doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGM
Founded2018
Employees404
Websitemirumpharma.com
ISINUS6047491013
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Chronic DiseasesNeurologyHepatologyCentral Nervous SystemGastroenterologyBiotechnologyHealth CarePharmaceuticalTherapeutics

Description

Mirum Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is dedicated to transforming the treatment of rare diseases. The company has three approved medicines: LIVMARLI (maralixibat) (‘Livmarli’), CHOLBAM (cholic acid) capsul…

Analysis

Middle-of-the-road

Mirum Pharmaceuticals, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 4/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
55
2026

All-time high

82

Mar 2026

All-time low

55

Jun 2026

Average rank

69

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
26
—
—
—
Price/Earnings
79
—
—
—
Price/Book
1
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
21
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Mirum Pharmaceuticals with its peers
Enanta Pharmaceuticals
NSQ:ENTA
62
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Rezolute
NAQ:RZLT
53
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Contineum Therapeutics
NSQ:CTNM
80
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Opus Genetics
NAQ:IRD
52
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Moderna
NSQ:MRNA
20
CountryUSA
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →
Kura Oncology
NSQ:KURA
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →